General Development Plan. All Development activities, and Manufacturing activities relating to Development, will be conducted pursuant to a reasonably detailed and written development plan prepared by Allergan that contains key Clinical Trials planned and estimated timelines (the “Development Plan”), provided that Allergan shall have the right to conduct any activities that are not described or contemplated by the Development Plan in furtherance of the goals of the Development Plan, with Allergan to use good faith efforts to describe any such material activities in a subsequent Development Plan or in the updates provided under Section 4.1(d). The initial Development Plan is attached hereto as Exhibit B. The initial Development Plan, and all amendments thereof, will include Allergan’s plan for seeking Regulatory Approval for a Licensed Product for the treatment of wet AMD and at least one additional Indication in the U.S., ***. In the event of any inconsistency between the Development Plan and this Agreement, the terms of this Agreement shall prevail. Except for those activities allocated to Molecular Partners in the Handover Plan, Allergan shall be solely responsible for all Development of Licensed Compounds or Licensed Products in the Field. In conducting such Development activities, Allergan shall document all Clinical Trials in formal written study records according to applicable Laws, including applicable national and international guidelines such as ICH, GCP, GLP and GMP. Molecular Partners shall perform any activities allocated to it under the Handover Plan in accordance with applicable Laws.
General Development Plan. The General Development Plan has been prepared and approved by the Parties and is annexed to and made part of this Agreement as Appendix A. The General Development Plan outlines (i) all current and planned clinical studies and/or protocols, (including, but not limited to the amended protocol in the Field to add an endpoint measuring time to recurrence of disease) for completion of the Phase III Clinical Trial, and (ii) estimated timelines for completion of clinical and manufacturing tasks to be undertaken to support the Registration of the Product, taking into consideration the requirements of the FDA. The General Development Plan shall be updated annually by incorporation of the Annual [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Development Plan(s) and may be further amended, at any time and from time to time, as approved by the JDC.
General Development Plan. Notwithstanding any other provision of this Agreement to the contrary, Landowner shall be required to enter into a General Development Plan(s) in conjunction with Subsequent Entitlements and shall not be able to develop the Property, or any portions thereof, until Xxxxxxxxx has entered into a General Development Plan(s).
General Development Plan. Subject to and in accordance with this Article 5, following exercise of an Option for a Collaboration Target Combination, and through the end of the JSC Term for a Licensed Product for such Collaboration Target Combination, Allergan and Molecular Partners will collaborate and cooperate to Develop such Licensed Product. All such Development activities, and Manufacturing activities relating to such Development, will be conducted pursuant to a reasonably detailed and written development plan prepared by Allergan within a reasonable time following the exercise of such Option (a “Development Plan”); provided that (i) Allergan shall have the right to conduct activities that are not described or contemplated in such Development Plan in furtherance of the goals of this Agreement, and Allergan shall describe any such material activities in subsequent updates to such Development Plan or in the reports provided under Section 5.2(d) and (ii) Allergan may not include any activities in such Development Plan to be conducted by Molecular Partners without Molecular Partners’ prior written consent. In the event of any inconsistency between such Development Plan and this Agreement, the terms of this Agreement shall prevail. Except for those activities allocated to Molecular Partners in such Development Plan, Allergan shall be solely responsible for Development of all such Licensed Products in the Field. In conducting such Development activities, Allergan shall document all Clinical Trials in formal written study records according to applicable Laws, including applicable national and international guidelines such as ICH, GCP, GLP and GMP. Molecular Partners shall perform any activities allocated to it under such Development Plan in accordance with applicable Laws. Following the JSC Term for such Licensed Product, Allergan shall have no further obligation to (1) conduct the Development activities for such Licensed Product in accordance with such Development Plan or (2) update, revise, or otherwise modify such Development Plan, but shall otherwise be required to conduct its Development activities in accordance with this Agreement.
General Development Plan. Developer shall consult with Project Manager to ascertain requirements of the Project Improvements and to prepare a GDP.
17.1.4.1 The GDP shall conform to the Park Recreation Board Policy No. 1011, the Consultant’s Guide to Park Design and Development, and include, but not be limited to the following, if applicable:
17.1.4.1.1 Sketches with sufficient detail to illustrate the scale and location of Project Improvements components.
17.1.4.1.2 Floor plans with sufficient detail to illustrate the scale and relationship of building components, exterior elevations and exterior colors, textures and materials.
17.1.4.1.3 Analysis of parameters affecting design and construction for each alternative considered.
17.1.4.1.4 Description and recommendation for structural, mechanical and electrical systems, showing alternatives considered.
17.1.4.1.5 Probable construction costs for the base Project Improvements and all additive alternates considered.
17.1.4.1.6 Summary of Project Improvements requirements and a recommendation.
General Development Plan. Within 180 days of the date of this Agreement, the Parties shall jointly prepare a general development plan (the “General Development Plan”) for the Project, including a description of the Project as well as projected timelines for its development, including the dates by which essential elements of each Phase of the Project are scheduled be completed. The Parties agree to use commercially reasonable and diligent efforts at all times to adhere to the timelines, goals and other terms set forth in the General Development Plan.
General Development Plan. The General Development Plan and Specific Development Plan for the Property approved by the Village Board on November 16, 2015 and any approved amendments thereto.
General Development Plan. (GDP) - The GDP gives a comprehensive description of a timber disposition holders proposed harvest strategy, road building plans for a five year period, and reclamation operations for a two year period, and includes all licences and permits. The GDP is used to guide integration of activities (see section 4.1.2).
General Development Plan. A General Development Plan for the entire “Mayowood Estates” project was approved by the Rochester Town Board on June 11, 2020, with the zone change. The approved General Development Plan contained 48 single family lots shown in EXHIBIT C. Upon acceptance of the Developer’s voluntary delivery of an EAW the Developer intends to amend the General Development Plan, in the future of “Mayowood Estates” to provide for up to 66 single family lots in accordance with the Traffic study prepared by SEH, Inc., and accepted by the Town Board on May 14, 2020. This Agreement will be amended with subsequent future development phases as additional lots are platted.
General Development Plan. ADDED A.; B.; C.; D.; E. AMENDED 12/12/83 AMENDED 6/24/83 [REPLACED] AMENDED 6/29/98 “The development of Parcels “A” and “C” of the Premises shall be in accordance with the Development Plan (sometimes herein referred to as the Master Plan and as the Precise Plan of development) for the Premises approved by the City Manager, which plan is filed in the Office of the City Clerk and identified as Document No. 762202. The development of Parcel “B” of the Premises shall be in compliance with the adopted Mission Bay Park Master Plan for Land and Water Use, 1976. Changes to the Development Plan shall be made only after written approval thereof by the City Manager. Parcel “A” Property 2 shall be developed in two phases. Phase 1 shall be developed according to the Development Plan for Parcel “A” Property 2 on file in the office of the City Clerk. Construction of Phase 1 shall commence on or before April 1, 1979 and shall proceed diligently to completion subject to the issuance of various authorizations and permits necessary for such development and delays beyond LESSEE’S control. Phase 2 development will be the subject of several reviews including the review and approval of the State of California Coastal Commission, the specific elements of Phase 2 have not, therefore, been determined at this time. On or prior to January 1, 1980, a Phase 2 Development Plan will be submitted to the City Manager for the City Manager’s approval, which approval will not be unreasonably withheld. In the event the Phase 2 Development Plan as initially submitted is not approved by the City Manager, such Plan will be modified and resubmitted until the City Manager’s approval is obtained. Construction of Phase 2 shall commence within two years after obtaining the City Manager’s approval and shall proceed diligently and without undue delay to completion, but subject to delay resulting from causes beyond LESSEE’S control.
5. The effective date of this Lease Amendment shall be the date of execution by the City as hereinafter provided. The increase in minimum rent shall be prorated from the effective date for the remainder of the current lease year.
